Allergan’s skincare system to incorporate Histogen’s technology

Allergan has selected regenerative medicine firm Histogen’s growth factor technology for its Regenica Advanced Rejuvenation System.

Regenica features a multipotent resignaling complex (MRCx), which is made of soluble cell-signalling proteins and growth factors that are said to support epidermal stem cells of the body involved in skin rejuvenation.

The cell conditioned media is intended to stimulate cells to become multipotent and naturally produce the proteins required for renewal of the skin.

Allergan SkinMedica research and development (R&D) vice-president Rahul Mehta said: “Histogen has developed a next-generation regenerative cell technology, harnessing the power of growth factors and stem-cell signalling molecules for skin rejuvenation that complements Allergan’s flagship growth factor technology, TNS.

“In addition to the Regenica product line, we are looking forward to collaborating with Histogen and leveraging their science to further bolster SkinMedica’s commitment to evidence-based skincare.”

Allergan recently acquired the Regenica Advanced Rejuvenation System, which comprises six products from Suneva Medical. 

Histogen founder Dr Gail Naughton said: “Allergan's world-class medical aesthetics portfolio, global footprint, history, and commitment to developing innovative aesthetic products make them ideally suited to realise the maximum potential of the Regenica growth factor technology for continued innovation in skincare.”

Regenica is currently available for purchase through medical aesthetic professionals.